Madrigal Pharmaceuticals
(NASDAQ:MDGL)
$204.0001
-0.6499[-0.32%]
Last update: 8:09AM Get Real Time Here
Q1 2024 Earnings in 12 days from now on Tue May 7th, before the market open
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Madrigal Pharmaceuticals Stock (NASDAQ:MDGL), Quotes and News Summary

Madrigal Pharmaceuticals Stock (NASDAQ: MDGL) stock price, news, charts, stock research, profile.

Open$200.630
Close-
Volume / Avg.208.116K / 579.203K
Day Range190.730 - 200.970
52 Wk Range119.760 - 322.670
Market Cap$4.278B
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
28
Short Interest
19.04%
Days to Cover6.19

Recent News

Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.
Avi Kapoor
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease. Availability is slated for April in the U.S.
Vandana Singh
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported fourth-quarter financial results.
Avi Kapoor
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Nov 23
1
Jan
2
Feb
13
1
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
About Madrigal Pharmaceuticals Inc
Sector
Health Care
Industry
Biotechnology
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the develo...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
MDGL
IMVT

FAQ

Q

How do I buy Madrigal Pharmaceuticals (MDGL) stock?

A

You can purchase shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Madrigal Pharmaceuticals's (MDGL) competitors?

A

Other companies in Madrigal Pharmaceuticals’s space includes: Immunovant (NASDAQ:IMVT), IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Ionis Pharmaceuticals (NASDAQ:IONS) and Alkermes (NASDAQ:ALKS).

Q

What is the target price for Madrigal Pharmaceuticals (MDGL) stock?

A

The latest price target for Madrigal Pharmaceuticals (NASDAQ: MDGL) was reported by B of A Securities on Monday, April 22, 2024. The analyst firm set a price target for 150.00 expecting MDGL to fall to within 12 months (a possible -26.47% downside). 31 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Madrigal Pharmaceuticals (MDGL)?

A

The stock price for Madrigal Pharmaceuticals (NASDAQ: MDGL) is $204.0001 last updated Today at April 25, 2024 at 8:09 AM EDT.

Q

Does Madrigal Pharmaceuticals (MDGL) pay a dividend?

A

There are no upcoming dividends for Madrigal Pharmaceuticals.

Q

When is Madrigal Pharmaceuticals (NASDAQ:MDGL) reporting earnings?

A

Madrigal Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 7, 2024.

Q

Is Madrigal Pharmaceuticals (MDGL) going to split?

A

There is no upcoming split for Madrigal Pharmaceuticals.

Q

What sector and industry does Madrigal Pharmaceuticals (MDGL) operate in?

A

Madrigal Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch